Healthcare and life sciences entered 2026 with a different tone than the last few years. There’s cautious optimism, but also real pressure. Capital is starting to move. IPO conversations are back on the table. Consolidation is picking up. And at the same time, growth expectations are higher and investor patience is lower.
From our work with private equity investors, growth funds, boards, and executive teams, several themes are emerging across the sector. Companies have largely stabilized operations, and attention is shifting to value creation, disciplined growth, and navigating a more complex market environment.
This piece is the first in a two-part series examining healthcare and life sciences in 2026, starting with the market dynamics shaping the sector.
Healthcare & Life Sciences Market Trends: What We’re Seeing in 2026
- Biotech rebound, led by tech-enabled bio. We’re seeing renewed momentum in biotech, especially where technology leads the story. The shift is toward tech-first bio rather than traditional biotech. AI is increasingly embedded in clinical development and therapeutic discovery. For example, a record 258 AI-enabled devices were authorized by the FDA in 2025 alone, with 1,300 authorized since 1995.
- Public markets reopening slightly. The IPO window isn’t wide open, but it’s no longer closed. Several IPOs at the end of last year and early this year have started to change sentiment. And the tone has changed enough that the industry press is openly talking about biotech IPOs being back in 2026.
- Consolidation is accelerating. Assets are coming to market, changing hands, and being combined by private equity firms to build larger platforms. In hospital and health system M&A, 43.5% of 2025 announced transactions involved a financially distressed party. In life sciences, global M&A hit $240B in 2025, up 81% from 2024.
- Payer services and payer IT are heating up. Private equity firms are actively looking for executives-in-residence and future CEOs in payer services and payer IT.
- Cost pressure remains intense. Healthcare costs are out of control for many organizations and end users. For example, average family premiums for employer sponsored insurance reached $26,993 in 2025, with workers contributing $6,850 on average. Investors and operators are focused on fraud, waste, and abuse while also delivering more cost-effective care models.
- Consumerism hasn’t slowed. Leaders are expected to meet consumers where they are through retail models, hybrid care, and more accessible delivery.
- Workforce shortages and burnout persist. Post-COVID staffing challenges remain. Organizations are adopting AI scribes and automation to reduce administrative burden and keep clinicians focused on patients. There’s evidence these tools help; one study found practitioner burnout fell from 51.9% to 38.8% after 30 days using an ambient AI scribe. Technology platforms are also expanding clinicians’ reach, allowing them to care for patients in remote locations and support hospital-at-home programs through telehealth, remote monitoring, and coordinated virtual care.
AI’s Impact on Healthcare & Life Sciences
- AI is embedded in every function. Leaders are applying AI within their specific area of a business, whether that’s commercial, operations, or clinical development. Healthcare has historically been slower to adopt new technologies, but AI adoption is moving quickly across the sector. Research from McKinsey found that 85% of healthcare leaders were exploring or had already adopted AI capabilities.
- Practical use cases matter. Leaders are focused on using practical AI for revenue cycle management, claims review, coding, and documentation.
- Hybrid and virtual care are still evolving. AI is being used to streamline scheduling, virtual visits, billing, and payments, creating more seamless and engaging patient experiences.
- Drug discovery and clinical development. AI continues to play a growing role in accelerating timelines and improving decision-making.
- Adoption has been a challenge. The tools and interest are there, but many organizations have lacked leaders who could drive adoption and ROI. That’s shifting quickly as practical AI experience is now expected across many executive roles.
The market dynamics outlined here are setting the stage for the next wave of leadership and innovation across healthcare and life sciences. As capital returns, consolidation accelerates, and AI becomes more embedded across organizations, expectations for leadership are rising as well. In the next piece in our two-part series, we break down the executive talent trends emerging as companies look for leaders who can navigate this more demanding environment.
NU Advisory Partners is an AI-native retained executive search and advisory firm focused on senior executive, operating, and board positions. If you’re interested in learning more, get in touch here.
